Garth Lees-Rolfe
Director of Finance/CFO at INHIBIKASE THERAPEUTICS, INC.
Net worth: - $ as of 30/05/2024
Garth Lees-Rolfe active positions
| Companies | Position | Start | End |
|---|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Director of Finance/CFO | 30/03/2024 | - |
| Corporate Officer/Principal | 31/10/2022 | 30/03/2024 |
Career history of Garth Lees-Rolfe
Former positions of Garth Lees-Rolfe
| Companies | Position | Start | End |
|---|---|---|---|
| F-STAR THERAPEUTICS, INC. | Corporate Officer/Principal | 30/11/2021 | 31/10/2022 |
Training of Garth Lees-Rolfe
| Queensland University of Technology | Undergraduate Degree |
Statistics
International
| United States | 2 |
| Australia | 2 |
| United Kingdom | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Director of Finance/CFO | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Garth Lees-Rolfe
- Experience
